Management of patients over the age of 80 diagnosed with breast cancer: A single centre experience of treatment options and long term outcomes.
Association of Breast Surgery ePoster Library. Blane C. 05/13/19; 257097; P053
Ms. Christine Blane
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P053
Topic: Breast surgery
Background: Elderly breast cancer patients are less likely to undergo surgery than those under 50, 39% vs. 90%. We undertook this study to gain an overview of our current practice in treating elderly patients. Methods : Patients aged 80 years or older diagnosed with invasive breast cancer between 2008 and 2012 were identified from hospital database. Multiple variables were collected including: tumour biology, primary treatment, comorbidities and long-term outcomes. Results: 311 patients were identified in the study period of which 59 were excluded due to a lack of documentation. 45% (n=141) had upfront surgery and 33.1% (n=103) received primary hormone therapy.Surgical patients were younger (median 84) and fewer co-morbidities (median Charlson Comorbidity Score of 4). Primary hormone patients had a median age of 87 and a median Charlson score of 5.Most primary hormone patients received aromatase inhibitors, 90% (n=93) vs. 10% (n=10) who received Tamoxifen. 23 (22.3%) patients had disease progression of whom 52% (n=12) received alternative hormone therapy, 30% (n=7) received radiotherapy and 21% (n=5) had surgery. Median time to progression was 17 months (n=2-79).Surgical patients had a significantly greater 5-year survival, 74% (n=105) compared to 36% (n=39). Almost 80% (n=82) primary hormone patients died with a median time from diagnosis to death of 24 months (1-84). Conclusions:A higher proportion of elderly patients treated in Gloucester have surgery than the national average (45% vs 39%). Surgical patients tend to be younger with fewer co-morbidities. Primary hormone therapy is a suitable treatment in high-risk surgical candidates.
Topic: Breast surgery
Background: Elderly breast cancer patients are less likely to undergo surgery than those under 50, 39% vs. 90%. We undertook this study to gain an overview of our current practice in treating elderly patients. Methods : Patients aged 80 years or older diagnosed with invasive breast cancer between 2008 and 2012 were identified from hospital database. Multiple variables were collected including: tumour biology, primary treatment, comorbidities and long-term outcomes. Results: 311 patients were identified in the study period of which 59 were excluded due to a lack of documentation. 45% (n=141) had upfront surgery and 33.1% (n=103) received primary hormone therapy.Surgical patients were younger (median 84) and fewer co-morbidities (median Charlson Comorbidity Score of 4). Primary hormone patients had a median age of 87 and a median Charlson score of 5.Most primary hormone patients received aromatase inhibitors, 90% (n=93) vs. 10% (n=10) who received Tamoxifen. 23 (22.3%) patients had disease progression of whom 52% (n=12) received alternative hormone therapy, 30% (n=7) received radiotherapy and 21% (n=5) had surgery. Median time to progression was 17 months (n=2-79).Surgical patients had a significantly greater 5-year survival, 74% (n=105) compared to 36% (n=39). Almost 80% (n=82) primary hormone patients died with a median time from diagnosis to death of 24 months (1-84). Conclusions:A higher proportion of elderly patients treated in Gloucester have surgery than the national average (45% vs 39%). Surgical patients tend to be younger with fewer co-morbidities. Primary hormone therapy is a suitable treatment in high-risk surgical candidates.
P053
Topic: Breast surgery
Background: Elderly breast cancer patients are less likely to undergo surgery than those under 50, 39% vs. 90%. We undertook this study to gain an overview of our current practice in treating elderly patients. Methods : Patients aged 80 years or older diagnosed with invasive breast cancer between 2008 and 2012 were identified from hospital database. Multiple variables were collected including: tumour biology, primary treatment, comorbidities and long-term outcomes. Results: 311 patients were identified in the study period of which 59 were excluded due to a lack of documentation. 45% (n=141) had upfront surgery and 33.1% (n=103) received primary hormone therapy.Surgical patients were younger (median 84) and fewer co-morbidities (median Charlson Comorbidity Score of 4). Primary hormone patients had a median age of 87 and a median Charlson score of 5.Most primary hormone patients received aromatase inhibitors, 90% (n=93) vs. 10% (n=10) who received Tamoxifen. 23 (22.3%) patients had disease progression of whom 52% (n=12) received alternative hormone therapy, 30% (n=7) received radiotherapy and 21% (n=5) had surgery. Median time to progression was 17 months (n=2-79).Surgical patients had a significantly greater 5-year survival, 74% (n=105) compared to 36% (n=39). Almost 80% (n=82) primary hormone patients died with a median time from diagnosis to death of 24 months (1-84). Conclusions:A higher proportion of elderly patients treated in Gloucester have surgery than the national average (45% vs 39%). Surgical patients tend to be younger with fewer co-morbidities. Primary hormone therapy is a suitable treatment in high-risk surgical candidates.
Topic: Breast surgery
Background: Elderly breast cancer patients are less likely to undergo surgery than those under 50, 39% vs. 90%. We undertook this study to gain an overview of our current practice in treating elderly patients. Methods : Patients aged 80 years or older diagnosed with invasive breast cancer between 2008 and 2012 were identified from hospital database. Multiple variables were collected including: tumour biology, primary treatment, comorbidities and long-term outcomes. Results: 311 patients were identified in the study period of which 59 were excluded due to a lack of documentation. 45% (n=141) had upfront surgery and 33.1% (n=103) received primary hormone therapy.Surgical patients were younger (median 84) and fewer co-morbidities (median Charlson Comorbidity Score of 4). Primary hormone patients had a median age of 87 and a median Charlson score of 5.Most primary hormone patients received aromatase inhibitors, 90% (n=93) vs. 10% (n=10) who received Tamoxifen. 23 (22.3%) patients had disease progression of whom 52% (n=12) received alternative hormone therapy, 30% (n=7) received radiotherapy and 21% (n=5) had surgery. Median time to progression was 17 months (n=2-79).Surgical patients had a significantly greater 5-year survival, 74% (n=105) compared to 36% (n=39). Almost 80% (n=82) primary hormone patients died with a median time from diagnosis to death of 24 months (1-84). Conclusions:A higher proportion of elderly patients treated in Gloucester have surgery than the national average (45% vs 39%). Surgical patients tend to be younger with fewer co-morbidities. Primary hormone therapy is a suitable treatment in high-risk surgical candidates.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}